Earnings Call Excerpt
ARIAD Pharmaceuticals, Inc. (ARIA)
Q3 2008 Earnings Call Transcript
November 6, 2008 8:30 a.m. ET
Executives
Maria E. Cantor – Vice President, Corporate Communications and Investor Relations
Harvey J. Berger – Chairman and Chief Executive Officer
Edward M. Fitzgerald – Senior Vice President, Chief Financial Officer and Treasurer
Timothy P. Clackson – Senior Vice President and Chief Scientific Officer
Matthew E. Ross – Vice President, Commercial Operations
Analysts
Phil Nadeau – Cowen & Company
Howard Liang – Leerink Swann & Company
Sar Jeneeve – JP Morgan
Eun Yang – Jefferies & Company
Derek Jellinek – Susquehanna Financial Group
[Andrew] – Susquehanna Financial Group
Presentation
Operator
Thank you for holding for ARIAD Pharmaceuticals' third quarter 2008 investor conference call. At this time, all participants are in listen-only mode. Following the formal report, ARIAD management will open the lines for a question-and-answer period. Please be advised that this call is being taped at the company's request and will be archived on the company's website for two weeks from today. At this time, I would like to introduce Mr. Maria Cantor, ARIAD's Vice President Corporate Communications and Investor Relations. Please go ahead.
Maria E. Cantor
Good morning, and welcome to ARIAD's investor call to discuss our corporate developments and financial results for our third quarter and nine months to date. Joining me for this call are Dr. Harvey Berger, our Chairman and Chief Executive Officer; Ed Fitzgerald, our Senior Vice President, Chief Financial Officer and Treasurer; Dr. Tim Clackson, our Senior Vice President and Chief Scientific Officer; and Matthew Ross, our Vice President of Commercial Operations.
Before we get started, I would like to state that during this call we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and uncertainties such as those detailed in our Form 10-K for the year ended December 31, 2007 and other SEC filings that may cause actual results to differ materially from the results expressed or implied by such statements.
Now I would like to turn the call over to Dr. Harvey Berger for this morning’s opening remarks.
Harvey J. Berger
Thank you very much, Maria, and good morning to everyone. Thank you very much for joining us.
I would like to take a minute to frame this morning’s call. ARIAD is demonstrating strong operational executions on each of the corporate objective we established earlier this year, and the third quarter was no exception. We are focused on these goals and I am proud to say accomplishing all that we have said we would do in 2008, on schedule and on budget. We are having a very productive year and in the third quarter we continued to fulfill our corporate objectives and to advance our oncology pipeline.
- To read the full transcript on Seeking Alpha, click here »
